Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention for End point reduction in hypertension (LIFE) study

Journal of the American College of Cardiology

Volumn 45, Issue 5, 2005, Pages 705-711

  Wachtell, Kristian ^a,b,j   Hornestam, Björn ^c   Lehto, Mika ^d   Slotwiner, David J ^b   Gerdts, Eva ^e   Olsen, Michael H ^a   Aurup, Peter ^f   Dahlöf, Björn ^c   Ibsen, Hans ^a   Julius, Stevo ^g   Kjeldsen, Sverre E ^h   Lindholm, Lars H ⁱ   Nieminen, Markku S ^d   Rokkedal, Jens ^a   Devereux, Richard B ^b  

^a GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^e HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^f MERCK RESEARCH LABORATORIES   (United States)

^g UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^h UMEÅ UNIVERSITY HOSPITAL   (Sweden)

ⁱ ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^j Rigshospitalet   (Denmark)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTIVITAMIN K; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIGOXIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOSARTAN; VERAPAMIL;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; ARTIFICIAL HEART PACEMAKER; CONTROLLED STUDY; FEMALE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HOSPITALIZATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; SINUS RHYTHM; STROKE; SUDDEN DEATH;

EID: 20044388522     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2004.06.080     Document Type: Article

References (22)

1. A.D. Krahn, J. Manfreda, R.B. Tate, F.A. Mathewson, T.E. Cuddy The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study Am J Med 98 1995 476 484
2. E.J. Benjamin, P.A. Wolf, R.B. D'Agostino Impact of atrial fibrillation on the risk of death: the Framingham Heart Study Circulation 98 1998 946 952
3. P.K. Whelton Epidemiology of hypertension Lancet 344 1994 101 106
4. V. Fuster, L.E. Ryden, R.W. Asinger ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the North American Society of Pacing and Electrophysiology J Am Coll Cardiol 38 2001 1231 1266
5. D.G. Wyse, A.L. Waldo, J.P. DiMarco A comparison of rate control and rhythm control in patients with atrial fibrillation N Engl J Med 347 2002 1825 1833
6. B. Dahlöf, R.B. Devereux, U. de Faire The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension Study Am J Hypertens 10 1997 705 713
7. B. Dahlöf, R.B. Devereux, S. Julius Characteristics of 9,194 patients with left ventricular hypertrophy: the LIFE study Hypertension 32 1998 989 997
8. B. Dahlöf, R.B. Devereux, S.E. Kjeldsen Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol Lancet 359 2002 995 1003
9. P.M. Okin, R.B. Devereux, S. Jern Baseline characteristics in relation to electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan Intervention For Endpoint reduction (LIFE) in hypertension study The LIFE Study Investigators. Hypertension 36 2000 766 773
10. K.M. Anderson, P.W. Wilson, P.M. Odell, W.B. Kannel An updated coronary risk profile A statement for health professionals Circulation 83 1991 356 362
11. T.S. Tsang, G.W. Petty, M.E. Barnes The prevalence of atrial fibrillation in incident stroke cases and matched population controls in Rochester, Minnesota: changes over three decades J Am Coll Cardiol 42 2003 93 100
12. J.D. Curb, S.L. Pressel, J.A. Cutler Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension Systolic Hypertension in the Elderly Program Cooperative Research Group JAMA 276 1996 1886 1892
13. L. Hansson, A. Zanchetti, S.G. Carruthers Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial HOT Study Group Lancet 351 1998 1755 1762
14. S.E. Kjeldsen, A. Westheim, I. Os New vs. old antihypertensive drugs (letter) Lancet 356 2001 1929 1930
15. J. Herlitz, J. Wikstrand, M. Denny Effects of metoprolol CR/XL on mortality and hospitalizations in patients with heart failure and history of hypertension J Card Fail 8 2002 8 14
16. D.L. Dries, D.V. Exner, B.J. Gersh Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials Studies Of Left Ventricular Dysfunction J Am Coll Cardiol 32 1998 695 703
17. H.V. Huikuri, A. Castellanos, R.J. Myerburg Sudden death due to cardiac arrhythmias N Engl J Med 345 2001 1473 1482
18. F. Boutitie, J.P. Boissel, S.J. Connolly Amiodarone interaction with beta-blockers: analysis of the merged EMIAT (European Myocardial Infarct Amiodarone Trial) and CAMIAT (Canadian Amiodarone Myocardial Infarction Trial) databases The EMIAT and CAMIAT Investigators Circulation 99 1999 2268 2275
19. E. Gerdts, L. Oikarinen, V. Palmieri Correlates of left atrial size in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study Hypertension 39 2002 739 743
20. E.J. Benjamin, R.B. D'Agostino, A.J. Belanger, P.A. Wolf, D. Levy Left atrial size and the risk of stroke and death The Framingham Heart Study Circulation 92 1995 835 841
21. Centers for Disease Control and Prevention. NHANES 1999-2000 public data release file documentation. Available at: http://www.cdc.gov/nchs/about/major/ nhanes/currentnhanes.htm 2004. Accessed January 15, 2004.
22. B. Dahlöf, T.A. Burke, K. Krobot Population impact of losartan use on stroke in the European Union (EU): projections from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study J Hum Hypertens 18 2004 367 373